Crossmark

Efficacy and safety of a combination of platelet-rich plasma with non-crosslinked hyaluronic acid versus a crosslinked hyaluronic acid, in single-injection for knee osteoarthritis. Randomized, controlled, multicenter, non-inferiority trial

Crossref DOI link: https://doi.org/10.1186/s12891-026-09625-z

Published Online: 2026-02-25

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Riglet, Louis

Delgado, Thomas

Lopez, Rosanna Ferreira

Pers, Yves-Marie

Cyteval, Catherine

Adam, Philippe

Ornetti, Paul
License Information

Text and Data Mining valid from 2026-02-25

Version of Record valid from 2026-03-31
More Information

Article History

Received: 1 December 2025

Accepted: 12 February 2026

First Online: 25 February 2026

Declarations

:

: This therapeutic trial involving human participants (ClinicalTrials.gov: NCT03328728) was conducted in accordance with the Declaration of Helsinki. The study was approved by the Local Ethics Committee (CPP Sud-Ouest et Outre-Mer I, Toulouse, France; approval no. 1-16-06) on June 21, 2016, and by the French National Agency for Medicines and Health Products Safety (ANSM; approval no. 160703B-12) on September 20, 2016.

: Not applicable.

: The authors declare no competing interests.

: Participants gave their written informed consent to take part in this study. Informed consent was obtained from all subjects involved in the study.

Document is current

Any future updates will be listed below